Abstract: T cells develop within the unique microenvironment provided by the thymus. T cell differentiation involves a series of commitment events and developmental checkpoints including T cell receptor (TCR) gene recombination and positive/negative selection of developing thymocytes to yield functionally mature T cells. These events occur in a sequential, temporal and spatial fashion, as developing thymocytes migrate through the thymus. In vitro studies to yield insights into human T cell development have classically employed the fetal thymic organ culture (FTOC) model system. This approach relies on the seeding of human hematopoietic stem cells (HSCs) and/or their progeny into host thymic lobes or thymic fragments, typically of mouse origin. Recently, a novel in vitro approach that makes use of the OP9 bone marrow stromal cell line expressing the Notch receptor ligand Delta-like-1 (OP9-DL1) effectively supported the generation of large numbers of human progenitor T cells from HSCs. In this review, we outline several in vitro systems employed for the generation and study of human T cells. Particular emphasis is dedicated to the OP9-DL1 coculture system. Finally, given the number of progenitor T cells that can be generated in vitro, we discuss the potential implications for the treatment of immune-related diseases such as cancer, immunedeficiency, and autoimmunity.
INTRODUCTION
T cells are the major cellular arm of the immune system that elicit potent and specific immune responses against bacterial and viral pathogens. T cell development requires a thymus. This now obvious observation is supported by a subset of primary (inherited) clinical immunodeficiencies in which thymic aplasia/ hypoplasia results in T cell immunodeficiency [1] . Most prominent is complete DiGeorge syndrome, a congenital and genetically-linked disease in which abnormal development of the third pharyngeal pouch during the 6 th -10 th week of gestation prevents the formation of the thymus and thus a complete absence of T cells [2, 3] . Normal T cell development can be rescued in patients with DiGeorge syndrome following allogeneic transplantation of fetal thymic fragments [4, 5] . The treatment of DiGeorge syndrome illustrates two important concepts: first, it establishes the thymus as a unique microenvironment capable of sustaining T cell development without addressing the molecular rationale for this dependency; and second, it establishes that whole organ transplantation may be used successfully to treat one rare form of primary T cell immunodeficiency in vivo provided this fetal tissue is available.
Like the in vivo setting, the development of T cells in vitro has until recently also required donor thymic tissue. Recent insights into the key molecular players responsible for the thymic dependency of T cell development has permitted the differentiation of expanded hematopoietic progenitor *Address correspondence to this author at the Department of Immunology, University of Toronto, Sunnybrook Research Institute, 2075 Bayview Avenue, Room A-331, Toronto, Ontario M4N 3M5, Canada; Tel: (416) 480-6112; Fax: (416)-480-4375; E-mail: jc.zuniga.pflucker@utoronto.ca cells into T cells by the use of a simple culture system. In this review we outline in vitro systems that recapitulate the early stages of human T cell development and hematopoiesis. Particular attention is given to the advantages of the OP9-DL1 stromal cell system, as well as highlighting the obstacles to be overcome in order to realize the therapeutic potential of in vitro derived T cells.
HUMAN DEVELOPMENTAL HEMATOPOIESIS
All cells of the erythroid, myeloid, and lymphoid lineages are derived from pluripotent hematopoietic stem cells (HSCs), which typically express the sialomucin-like adhesion CD34 and lack lineage-specific markers (CD34 + Lin -) [6, 7] . In the adult, most hematopoietic cells are generated in the bone marrow, which also supports in distinct niches HSC self-renewal [8, 9] , myelo-erythropoiesis, and B cell development [10] . Conspicuously absent from the bone marrow is the process of T lymphopoiesis, which requires a thymus for the differentiation of HSC-derived thymic seeding cells [11] [12] [13] [14] [15] .
Models depicting human hematopoiesis and lymphocyte development have relied extensively on studies with mice due to the ability to readily obtain purified precursor cells and the capacity to test in vivo for reconstitution of hematopoietic lineages [16] . Thus, hematopoiesis is modeled hierarchally; whereby the most primitive pluripotent HSCs differentiate into more restricted progenitor cells that in turn receive signals from local environmental niches, such as the bone marrow or thymus, to further differentiate along one of 9 possible lineages. This is evidenced both in vitro and in vivo by the loss of CD34 expression followed by the concomitant gain of lineage specific markers on stem cell progeny [17] [18] [19] .
The classical interpretation of this model hierarchy is that it is subordinately unidirectional. Hence once differentiation ensues, lineage restriction follows. This tenet implies certain assumptions. First, progenitor cells of reasonable frequency and high purity can be isolated as a population and then tested on the clonal level for multipotency in differentiation assays. Second, progenitor cells receive cues from the local environment that selects out or directs a differentiation program. Finally, differentiating cells undergo a combination of cellular and/or genetic changes that define it sequentially along the differentiation program. With regard to human hematopoiesis many of these assumptions were difficult to test until recently. However, the availability of immunodeficient mouse strains that engraft human HSCs and progenitor cells, fetal thymic organ cultures (FTOC) and their derivatives, as well as new in vitro stromal coculture techniques, such as the OP9-DL1 system, have permitted a closer inspection of T lymphocyte development.
HUMAN LYMPHOID PROGENITORS
One of the early branch points in this developmental hierarchy is the decision whether a HSC will differentiate along the lymphoid or myeloid lineages [20] . It is generally accepted that B, NK, and T cells are derived from a lymphoid precursor [21] while cells of the granulocytic/monocytic lineages are derived from a myeloid precursor [22] . Several types of lymphoid progenitor cells have been identified and isolated from the bone marrow, in mice and humans (reviewed in [23] ). Several bone marrow cell populations have been reported to generate T cells efficiently upon contact with a thymic microenvironment [24] [25] [26] . Bhandoola's group was the first to isolate a Lin -Sca-1 hi , c-kit hi (LSK) population of progenitor cells in the blood and to demonstrate these cells can efficiently seed the thymus suggesting that these cells may represent physiological circulating thymic progenitors [25, 27] .
Unlike their mouse counterparts, the isolation and identification of human thymic progenitors has proven more elusive. Historically, this has been due in part to a lack of shared common markers between mouse and human progenitors and the inability to rigorously test progenitor cell potential in humans. The strongest marker for identifying potential thymic progenitors in humans is CD34. However, as it is also expressed on HSCs, CD34 comprises a heterogenous population of cells with full hematopoietic and limited lineage potential. Thus, several groups have used CD34 in their search to identify human progenitor cells with myeloid or lymphoid restricted potential.
In this review, we use the term lymphoid progenitors, which may include thymic progenitors as well as other multilineage progenitor cells, to describe a heterogenous population of cells with T, B, NK and DC lineage potential. With regard to human studies, this distinction is important to note as several independent groups have characterized progenitor cells from several sources using different methodologies [28, 29] . For example, it is possible that progenitor cells from fetal liver, fetal bone marrow, umbilical cord blood, adult bone marrow, and adult thymus may possess differences in lineage restriction. In addition, the use of dissimilar antibodies with poor separation and/or low intensity of cell surface expression of critical markers, such as CD10 or CD7, on progenitor cells may allow for the inclusion of populations of cells that should be excluded or alternatively exclude cells that express cell surface markers at lower levels. Moreover, the technical limitations associated with early in vitro assays, such as FTOC, did not permit the testing of T cell potential at the single cell level. Additionally, access to human tissue is often limited.
Terminal deoxynucleotidyl transferase (TdT) was one antigen expressed on CD34 + cells hypothesized to represent a lymphoid precursor cell with B and T potential [30, 31] . However, as TdT is expressed intranuclearly, non-viable staining procedures to detect it did not permit functional assessment of the lineage potential of these cells. Greater than 50% of the CD34 + TdT + cells expressed the common acute lymphoblastic leukemia antigen (CALLA) CD10 making it a useful marker for identifying cells with shared T and B potential. Galy 
CD10
+ cells are rare, they may serve as a precursor cell to all lymphoid lineages. This remains to be proven experimentally on the clonal level [28] . Indeed in our own studies, progenitor T cells derived from CD34 +
CD38
-cord blood progenitor cocultured on the OP9-DL1 cells did not reveal expression of CD10 on CD7 + cells [19] (data not shown).
Recently, Haddad and colleagues undertook a developmental analysis of human fetal thymus. The earliest thymic colonizing cell detected exhibited the CD34 hi CD45RA hi CD7 + phenotype [36] . These cells could also be detected in fetal bone marrow, but not in fetal liver, suggesting, that the bone marrow is the primary site for the production of progenitor cells that colonize the human thymus at 8-9 weeks of gestation. Furthermore, bone marrow derived CD34 hi CD45 RA hi CD7 + cells gave rise to T cells in FTOC. Similarly, cord blood derived CD34 hi CD45RA hi CD7 + cells generated T cells upon coculture with OP9-DL1 cells and displayed a strong capacity to enter thymus parenchyma in an ex vivo colonization assay. Collectively, the aforementioned studies strongly support the notion that human lymphoid progenitors express the CD34 hi CD45RA hi CD7 + as outlined in the developmental model by Blom et al. [28] . While these candidate lymphoid progenitors derived from bone marrow and cord blood give rise to T cells, as well as B, NK, and DC cells, they still need to be compared in parallel and functionally assessed for T cell development at the single cell level. This is now possible with the OP9-DL1 coculture system.
HUMAN THYMIC DEVELOPMENT AND PROGENI-TOR CELL COLONIZATION
The thymus is the primary site of T lymphopoiesis [11] [12] [13] [14] [15] . This specialized organ emerges rudimentarily from the third pharyngeal pouch between 4-5 weeks of gestation and is seeded by blood-borne hematopoietic progenitor cells between 8-9 weeks [37] [38] [39] [40] . Within a week, mature T cells expressing -or -T cell receptors (TCR) are detectable in the thymic parenchyma. By 14-16 weeks of gestation, corticomedullary partitioning has established the definitive thymic architecture observed in the adult [41] [42] [43] .
Unlike the bone marrow, the thymus lacks the capacity to support HSC self-renewal [44, 45] . Thus, in order to maintain T cell numbers in the periphery, the thymus must intermittently recruit blood-borne progenitor cells from the bone marrow [46] . There is evidence to suggest that the export of thymic progenitor cells from the bone marrow is coordinated with the ability of the thymus to accept new immigrants [47] . Once inside, these progenitor cells undergo differentiation in a temporal and spatial manner that has been well documented in mice [11, 48, 49] . The exact identity of these progenitor cells is of some debate [25, 28, [50] [51] [52] , but it is generally accepted that the thymus can be seeded by multiple types of progenitor cells albeit with different efficiencies [36, 53, 54] .
THYMOCYTE RECRUITMENT AND MIGRATION
Studies in mice have revealed that T cell development in the thymus is spatially and temporally regulated. Progenitor cells enter the adult thymus in a coordinated and gated manner [55] via blood vessels at the cortico-medullary junction [56] where they migrate towards the subcapsular region of the cortex and then reverse towards the medulla [57, 58] . Recently, Rossi et al. demonstrated that the recruitment of thymic progenitor cells is regulated by P-selectin and its ligand PSGL-1 [59] . In this study, the thymus of PSGL-1 -/-mice contained fewer thymic progenitor cells and had more empty niches than their wild-type controls. Moreover, realtime RT-PCR studies, indicated that P-selectin expressed on thymic epithelium was dynamically modulated by the number of resident thymic progenitor cells. Taken together, the regulation of P-selectin by a sensor that detects thymic niche occupancy may serve to control progenitor cell access. A similar mechanism may be operational in the human thymus as P-Selectin/PSGL adhesion was reported to suppress hematopoiesis [60] .
How developing thymocytes traverse the thymus is not completely understood, but several chemokine gradients are believed to play prominent roles in both progenitor cell recruitment and localized differentiation of thymoctyes [61, 62] . Specifically, several studies have demonstrated Tlineage-specified progenitors are recruited to seed the thymus though the establishment of chemokine receptor/ligand gradients: CCR7 and CCR9/ CCL21 and CCL25 respectively [50, [63] [64] [65] . In addition, studies by Plotkin et al. have shown that CXCR4 facilitates the localization of early lymphoid progenitor cells to the cortical region of the thymus [66] . Additional studies have implicated that CCR7 is essential for cortex-to-medulla migration [67, 68] and for establishing central tolerance to self-peptides by positively selected thymocytes [69] . In contrast, negative selection, which is thought to mainly occur in the medulla, has been linked to the expression of the AIRE gene in medullary thymic epithelial cells. The AIRE genes codes for a nuclear protein that is essential for promiscuous expression of tissue-specific selfantigens [70, 71] . Indeed, AIRE deficiency results in autoimmune-polyendocrinopathy-candidiasis ectodermal dystrophy (APECED) in humans [72, 73] , which has been recapitulated in AIRE -/-deficient mice [74] [75] [76] .
HUMAN T CELL DEVELOPMENT IN VIVO
Human progenitor cells differentiate into T cells in the thymus via discrete developmentally-regulated steps that involve a series of commitment events and developmental checkpoints including T cell receptor (TCR) variable (V), diversity (D), and joining (J) gene segment rearrangements [V(D)J], and positive/negative selection of developing thymocytes [15, 28] (Fig. 1) . Traditionally, T cells have been defined based on the surface expression of CD4 and CD8 with thymocytes first starting as CD4 -CD8 -double negative (DN), then becoming CD4 + CD8 + double positive (DP), and lastly maturing into single positive (SP) CD4 + or CD8 + T cells. In humans, the DN population cannot be further subdivided into populations based on the surface expression of CD25 or CD44 as observed in mice. Rather, distinct surface markers such as CD1a and CD7 are used in combination with the status of T-cell receptor rearrangement [15, 77] . The earliest intrathymic progenitors express CD34, CD7 and CD45RA [36] , do not express CD1a, and are triple-negative (TN) for mature T cell markers: CD4, CD8, and CD3 [78] . At this stage, CD34 hi CD45RA hi CD7 + cells exhibit multilineage potential [28, 35, 36] and is consistent with reports the thymus can also support B, NK and DC development [28, [79] [80] [81] [82] [83] . Commitment to the T cell lineage is associated with the status of TCR gene rearrangement at the , and then loci (pre-T1 cells) in addition to the expression of CD1a by CD7-expressing pro-thymocytes [15, 28, 84, 85] . Progression to the next developmental stage termed pre-T2 is accompanied by the expression of CD4 in the absence of CD8 and is referred to as the CD4 + immature single-positive (CD4ISP) cell. The pre-T2 (CD4ISP) population has the potential to differentiate along both the -and -T cell lineages as both precursors are present within this population.
A major checkpoint in the development of -T cells is -selection, whereby progenitor T cells that have undergone a productive -locus gene rearrangement are selected for further differentiation. In the mouse -selection occurs at the DN3 (CD25 -CD44 lo ) stage [48] ; however in humans, -selection is known to proceed primarily downstream of CD4ISP stage. Since the -chain of the TCR has yet to undergo rearrangement, the -chain must covalently pair with the surrogate pre-TCR chain (pre-T ) and CD3 chains, collectively known as the pre-TCR, in order to be expressed on the cell surface. Signaling through pre-TCR results in intense rounds of proliferation, survival and allelic exclusion of further TCR alleles [86] . Pre-TCR signals induce CD4ISPs to proceed towards the double positive (DP) stage of development where thymocytes co-express the CD8 coreceptor on their surface in combination with CD3. As the CD8 molecule is a heterodimer of and chains, CD4 + CD8 + -early DPs precede CD4 + CD8 + + late DPs.
While in the mouse, -selection is associated with transition from the DN stage to the DP stage, this does not hold true for human thymocytes. Although -selection can be initiated at the CD4ISP stage, it is clear that this checkpoint can occur in cells having either CD4 alone, or in combination with CD8 + -or CD8 + + [84] . Recently, Joachims et al. demonstrated molecularly that -selection in humans has a prolonged developmental window [85] .
After -selection, rearrangements at the TCR locus are initiated. Once an in frame -locus gene rearrangement has occurred, the -chain pairs with a translated -chain to generate a mature -TCR expressing DP T cell that undergoes positive and negative selection events. Developing thymo- + blood-borne progenitors enter the thymus where they undergo T-lymphopoiesis. As maturation occurs, T cells undergo a variety of transitional stages, which can be discriminated on the basis of cell surface antigens. The earliest cells in the thymus bear high levels of CD34, CD45RA, CD7 and are negative for CD1a. As maturation occurs these cells gain CD1a on their surface (CD34 + CD1a + ), followed by CD4 resulting in a CD4ISP stage. CD4ISPs next upregulate the CD8 chain and are known as early DPs, which is followed by CD8 chain upregulation (late DPs). CD4 + CD8
+ + T cells subsequently upregulate TCR, and undergo selection events to become mature CD4 + and CD8 + T cells. Expression of preTalpha (pT ), TCRbeta (TCR ), and TCRalpha (TCR ) is shown as labeled arcs during development. The developmental windows for T cell lineage choice and -selection (labeled dotted lines) are also shown.
cytes that recognize low affinity interactions of self-peptides complexed with MHC antigens expressed on thymic epithelial cells within the cortex are rescued from death via a process called positive selection. Conversely, developing thymocytes that receive strong signals from self-peptides complexed with MHC expressed thymic dendritic cells and thymic epithelial cells within the medulla, undergo apoptosis via a process called negative selection.
Compared with the -T cell lineage, understanding of -T cell lineage is less complete. This is due in part to the absence of recognized lineage-specific markers as many mature T cells are predominantly CD4 -CD8 -DN or CD8 + SP and, unlike -T cells, variably express CD2 [87, 88] . In addition,
T cells represent only 1% of thymic lymphocytes making them difficult to study in large numbers. Finally, the maturation of T cells can proceed outside the thymus [89, 90] [85] . Recently, Taghon et al. reported that the level of expression of CD27 could be used to delineate the earliest stages of mouse progenitor T cells with or potential and to better understand the molecular requirements which influence the / decision [92] . Thus, unlike -T cells, the early stages in -T cell development remain obscure and require further investigation. With limited TCR diversity, -T cells function in both the innate and adaptive immune responses and are capable of producing cytokines [93] . Recently, it was demonstrated that human V 2V 2 + T cells, like dendritic cells, can function as professional antigen presenting cells (APCs) towards -T cells [94] .
NOTCH SIGNALING
It is now well established that T cell development requires sustained Notch signaling [95, 96] . In humans there are four Notch receptors [97] [98] [99] [100] , which can pair with two serrate like ligands (Jagged-1 & -2) [101, 102] or three Delta-like-ligands (Dll-1, -3 & -4) [103, 104] (Fig. 2) . HSCs express multiple Notch receptors [98, 105] , and distinct expression patterns of the various Notch ligands has been reported for bone marrow stromal cells [103, [106] [107] [108] [109] and thymic epithelial cells [110] . Taken together, these findings suggest that different Notch receptors and ligands may control different aspects of hematopoiesis depending on the micro-environment: allowing for self-renewal in the bone marrow and influencing cell fate decisions in the thymus [108] .
Notch signaling is initiated by ligand-receptor interactions between neighboring cells (Fig. 2) . This leads to two successive proteolytic cleavage events with the latter cleavage induced by a Presenilin-dependent -secretase. This results in the liberation of the intracellular portion of Notch (ICN) that translocates to the nucleus where it interacts with CSL (CBF1 in mammals; c-promoter binding factor 1; SuH in D. melanogaster; suppressor of hairless; Lag-1 in C. elegans) via its RAM domain [111] . This interaction converts CSL from a repressor of transcription into an activator. As the dysregulation of Notch signaling leads to T cell acute lymphoblastic leukemia (T-ALL) [112, 113] , the Notch signaling pathway is regulated at multiple levels. These include receptor endocytosis, glycosylation of both ligands and receptors by Fringe family members, and the interaction of numerous Notch modifiers that activate or repress target gene transcription [114] [115] [116] . For example, the recruitment of the coactivator Mastermind-like-1 (MAML1) is required for the transcriptional activation of Notch target genes such as Hairy Enhancer of Split (HES)-1 and HES-5. The net effect is that that intrathymic Notch signaling induced by the Notch ligand Delta-like-1 triggers T cell differentiation at the expense of other lineages (B cell and myeloid cell lineages) [117, 118] . Taken together, the outcome of Notch signaling imparts unique signals that support the differentiation of T cells within the thymus.
IN VITRO MODELS (ORGAN BASED) FTOC
Traditionally, the development of in vitro models to study human T lymphopoiesis and progenitor cell commitment have relied on the use of host thymic tissue obtained from fetal mice, or from electively terminated human fetuses, and from thymus tissue discarded during pediatric cardiac surgeries. Until recently, the only in vitro model system that permitted the generation of human T cells was the hybrid FTOC system first adapted by Fisher et al. [119] . In this whole organ based approach, embryonic day 14/15 mouse thymic lobes are depleted of endogenous thymocytes through treatment with 2-deoxyguanosine, seeded with hematopoietic progenitor cells via the hanging drop method and cultured for a period of time on GelFoam-rafts. T cell developmental stages can then be assessed at various time points following introduction of murine hematopoietic progenitors into the thymic rudiments. Using this hybrid human/mouse FTOC, Fisher et al. demonstrated the proliferation and generation of mature SP T cells from human fetal thymic progenitor cells [119] . This approach was also demonstrated later with postnatal human progenitor thymocytes [120] and human progenitor cells obtained from bone marrow and cord blood [121] . The study by Fisher et al. noted that efficient colonization of murine thymic rudiments by human thymic progenitor cells depended on the addition of human thymic stromal elements [119] . In order to improve thymic colonization and T cell development, several groups directly injected human progenitor cells into human fetal thymic fragments [78, 122] . Despite its inefficiency and technical complexity, hybrid human/mouse FTOCs are routinely used to examine human hematopoiesis and T cell differentiation [78, [123] [124] [125] [126] .
Modified FTOC
Although the FTOC system yielded great insight into T cell development, the capacity to determine lineage commitment of progenitor cells using in vitro clonal assays for T cell development remained technically challenging [127] . Kawamoto et al. was the first to report that this system could assay lymphoid potential of mouse progenitor cells on the clonal level [128] . Res et al. later adapted this system using CD34 + CD38 dim human fetal liver cells to assay for B and NK cell development on the clonal level and T cell development on the population level [129] . To study T cell development with lower numbers of progenitor cells, the FTOC system was modified further under high-oxygen submersion conditions [130, 131] . Although these advancements remained below the threshold for testing human T cell development at the clonal level, they nevertheless highlighted the role of oxygen in maintaining the function of the thymus [132] .
RTOC
While the FTOC system relied on intact fetal thymic lobes, the reaggregate thymic organ culture (RTOC) system was initially developed to determine the role of thymic stromal subsets in supporting T cell development [133] . As with the FTOC, the RTOC system relied on the 2-deoxyguanosine-mediated-depletion of host thymocytes followed by the disaggregation and/or purification of thymic stromal cell subsets. These purified thymic epithelial subsets were then reaggregated in defined ratios with purified progenitor cells, aliquoted as a slurry on Nucleopore membranes, cultured for a several weeks, and then assayed for T cell development. This approach was later utilized by several researchers seeking to overcome the inefficiency of seeding mouse and human progenitor cells observed in FTOC [134] [135] [136] [137] [138] . Recently, the RTOC system was employed to deter- mine the potential of human fetal gut CD3 -CD7 + cells to differentiate into CD3 + CD7 + T cells [139] . The RTOC approach has also been used in the construction of engineering 3-D thymic matrices.
Matrices
Several groups have utilized biocompatible matrices in tissue-engineering approaches to generate human T cells in vitro and in vivo. These approaches were based on the premise that the 3-D architecture of a thymus was required for T cell development [140] . As T cell development could be recapitulated in FTOC, but not in monolayer coculture of thymic stromal cells, the 3-D requirement of the thymic microenvironment emerged as dogma [110, 141] , even though the molecular rationale for this dependency remained unknown at the time. Poznansky et al. demonstrated that coculture of human CD133 -or CD34 + HSCs onto tantalum-coated carbon matrices seeded with murine thymic fragments could recapitulate the 3-D architecture of the thymus and support the differentiation of functionally mature T cells [142] . In a similar approach, Suematsu et al. demonstrated that a sponge-like collagenous scaffold coated with the murine thymic stromal cell line TEL-2 expressing lymphotoxin alpha (LT ), could generate lymphoid organs that contained both B and T cell areas upon implantation into SCID mice [143] . Following the molecular revelation that T cell development requires Delta-like-Notch ligands [19, 117, 118, [144] [145] [146] , Clark et al. demonstrated thymic-independent T cell development using human fibroblasts and keratinocytes arrayed onto Cell-foam matrices [147] . Specifically, T cell development was assigned to the capacity of these keratinocytes to induce Delta-like-1 expression following highdensity coculture and to express the FOXN1 transcription factor that supports thymic epithelial development. Furthermore, cultured skin cells expressed autoantigens, Hoxa3, and AIRE and were non-reactive to autologous but not allogeneic dendritic cells, indicating that negative selection was occurring in this system. As recurrent Notch signaling through Delta-like molecules is required for T cell development [95, 96] , our laboratory re-examined the reason for the failure of thymic stromal cells cultured as a monolayer to support Tcell development in vitro. Disruption of the 3-D structure of the thymus resulted in loss of Delta-like-1 and -4 expression by thymic stromal cells and abrogated T cell development, which could be restored upon ectopic re-expression of Deltalike-1 or -4 [148] . Although it is tempting to speculate that induced expression of Delta-like-1 on keratinocytes following high-density coculture conditions is directly linked to the density conditions present within the 3-D architecture of the matrix and thus supports T cell development, the study by Clark et al. [147] did not address the loss of 3-D structure on the expression of Delta-like-1 on keratinocytes nor the capacity of keratinocytes to support T cell development.
LIMITATIONS OF ORGAN-BASED MODELS
While the FTOC and its derivative systems yielded valuable insights into human T cell development, these systems presented serious drawbacks and limitations. First these systems were technically cumbersome requiring depletion of host thymocytes, direct microinjection of rare progenitor cells or tearing of limiting fetal thymic tissue for colonization, which was more than often inefficient. In addition, many of these systems did not lend themselves to sustainable long-term coculture nor scaling up to yield large numbers of progenitor T cells needed to impart therapeutic effectiveness in human disease. Taken together, these organ based systems underscored the need for a simple system to generate large numbers of T cells to be therapeutically relevant.
In Vitro Models (Stromal Based)
Introduced many years ago, bone marrow cell lines such as the S17 [149] [150] [151] , MS5 [152] , or OP9 [153] were shown to support the efficient generation of B cells [154] and natural killer (NK) cells [155, 156] following coculture with HSCs and the appropriate cytokine cocktail. Many of these stromal lines were adapted later to support the differentiation of human progenitor cells into B cells [157, 158] , NK cells [33, 35] , and dendritic cells [159] [160] [161] . In particular, the OP9 stromal cell line, introduced by Kodama and colleagues [153] supported early hematopoiesis and later B lymphopoiesis with limited myelopoiesis due to a deficiency of OP9 cells to produce macrophage-colony stimulating factor (M-CSF) [153, [162] [163] [164] [165] . These findings suggested that the OP9 cells might make an ideal stromal line for the generation of B, NK, and perhaps T cells by favoring lymphopoiesis over myelopoiesis. Strikingly absent from these cocultures, were T cells, suggesting that some intrinsic factor(s), extracellular matrix component, or cell receptor/ligand signal transduction pathway present within the thymus, but absent in bone marrow stromal lines, was required for T cell differentiation. Although the precise molecular mechanism for the thymic dependency of T cell development had not yet been elucidated, it was well established that T cell development in vivo required a thymus [4] .
Two seminal papers helped to further define the precise molecular rationale for the thymic dependency of T cells [117, 118] . Transplantation of hematopoietic precursors retrovirally transduced with constitutively activated Notch (ICN) receptors into syngeneic mice led to the development of double positive (CD4 + CD8 + ) T cells within the bone marrow [117] and produced T cell neoplasms [166] . Reciprocal experiments utilizing inducible inactivation of Notch-1 in bone marrow precursors blocked T cell development in the thymus, while enhancing thymic B cell differentiation [118, 167, 168] . Taken together these studies suggested that signaling though Notch-1 receptor plays a crucial role in affecting the developmental choice available to progenitor cells by inhibiting B cell development and favoring T cell development [168, 169] . These studies also suggested that Notch signaling had to be exquisitely regulated within tissues to promote the development of T cells within the thymus and B cells within the bone marrow.
Given the role of Notch signaling in T versus B cell decisions as well as the observation that OP9 cells support Bcell, but not T-cell, development, our laboratory undertook a closer examination of the Notch receptor ligands expressed by OP9 cells. While the OP9 cells expressed members of the Jagged family (Jagged-1 and Jagged-2), absent were members of the Delta-like family (Delta-like-1 and Delta-like-4) [145] suggesting that the failure of OP9 cells to support T cell development was due to absence of Delta-like molecules [170, 171] . To test this hypothesis, OP9 cells were retrovirally transduced with the Delta-like-1 gene (OP9-DL1) and cocultured with mouse HSCs. Not only did OP9-DL1 cells support the differentiation of T cells from mouse HSCs [145] and mouse embryonic stem cells (ESCs) [144] , it was quickly adapted to support the differentiation of human HSCs derived from umbilical cord blood [19] , bone marrow [172] , and granulocyte macrophage-colony stimulating factor (GM-CSF)-mobilized peripheral blood (La Motte-Mohs, unpublished data).
Of note and prior to our report using OP9-cells, Jaleco et al. evaluated S17 stromal cells engineered to ectopically express human Delta-like-1 (S17-DL1) or Jagged-1 (S17-JAG1) for their ability to support human lymphoid differentiation upon coculture with CD34
+ cord blood cells [146] . While S17-JAG1 cocultures generated a robust population of B cells ( + DP T cells emerged in S17-DL1 cocultures. Given the less stringent CD34 enrichment protocol employed, it is not clear from this study whether S17-DL1 cocultures supported de novo differentiation of CD34 + CD38 -cells or expansion of contaminating multilineage progenitor (CD34 + CD7 + ) cells. It is also not clear whether a longer coculture period would have permitted the emergence of more CD4 + CD8 + DP cells on S17-DL1 cells [146] , as was later reported with OP9-DL1 cells [19] . Regardless, it is clear from the aforementioned studies, that mouse and human Delta-like-molecules can support the robust generation/expansion of progenitor T cells. It is also conceivable that certain bone marrow stromal lines may better provide as yet undefined factors that enhance the differentiation of T cells.
OP9-DL1 COCULTURE SYSTEM
The ability to utilize simple stromal cell monolayers that express Delta-like-molecules such as OP9-DL1 cells or S17-DL1 cells has permitted a closer examination of human T cell development than was previously possible. Indeed at the time of submission of this article, the OP9-DL1 cells have been already distributed to nearly 400 laboratories around the world. Research emerging from these laboratories has confirmed the molecular elements required to sustain the generation of T cells [141, 173] from numerous sources of progenitor cells and has helped to elucidate many other factors with critical roles in T cell development [174] [175] [176] [177] [178] [179] [180] .
While the paradigm that T cell development requires signaling through Delta-like ligands has been firmly established for Delta-like-1 expression, it is beginning to emerge that Delta-like-4 expression can also recapitulate T cell development in vitro [170] . This is not surprising given that Delta-like-4 shares sequence homology with Delta-like-1 and is also expressed within the thymus [145] . Whether Delta-like-4 imparts distinct signals to a differentiating HSCs remains to be determined experimentally, but given the capacity of both Delta-like ligands [La Motte-Mohs, unpublished observation] to support human T cell development it is likely that Delta-like-4 shares many of the signaling mechanisms directed by Delta-like-1.
Prior to the advent of OP9-DL1 cells, the study of human T cell development required FTOCs and their derivative systems, which although functional, were inefficient, and impractical given the limitations of hybrid/mouse FTOCs and the lack of available human fetal thymic tissue. Thus, it was difficult to conceive how one could generate the numbers of human progenitor T cell needed to elicit therapeutic effectiveness for the treatment of immune-related disease. The OP9-DL1 technology has numerous advantages. Many of these advantages have been reviewed previously with an emphasis on mouse T cell development [171] and offer similar advantages with regard to the study of human T cell development.
An important practical consideration of the OP9-DL1 coculture system is its technical simplicity. Human HSCs are cultured directly on a simple monolayer with the addition of two human cytokines Flt-3L and IL-7 (Fig. 3) for long periods of time. Thus, with media changes and transfer onto new stroma, the OP9-DL1 cells are easily manipulated and readily expanded into larger cultures. This is in contrast to cumbersome FTOCs, which often require direct microinjection of human progenitor cells and have limited culture times. Given these constraints, the OP9-DL1 coculture system represents an improvement over FTOCs in that a single cell can be now assayed for T cell progenitor cell function [145, 181] . Although this was possible using FTOCs [182] [183] [184] , the feasibility of large-scale analyses was nearly prohibitive and there were no reports of progenitor frequency using single cell analysis for human progenitor T cells. Thus, together with the current assays presently used in FTOCs, our system can complement different approaches utilized in the study of human T cell development, opening new avenues for future research to test the immune reconstitution capabilities and immune function of in vitro-derived T cells [185, 186] .
Additionally, the OP9-DL1 system has been able to support generation of T cells from a number of defined sources. Mouse progenitor cells obtained from fetal liver, bone marrow, fetal thymus, and peripheral blood, and embryonic stem cells (ESCs) generate T cells upon OP9-DL1 coculture [20, 144, 145, 187] . Similarly, human progenitor cells isolated from fetal liver, bone marrow, fetal thymus, and umbilical cord blood generate T cells upon OP9-DL1 coculture [19, 29, 172] . With regard to ESCs and HSCs, the emerging uses of short interfering RNA (siRNA) [188, 189] and locked nucleic acids [190] as methods of choice to quickly assay for the functional importance of a particular gene, for instance during T cell development, can be easily adapted to the OP9-DL1 cell coculture system. This allows for a practical approach to characterize the role during T cell development of many genes that when deleted, result in an embryonic lethal phenotype and simply cannot be further studied. Similarly, the OP9-DL1 system is adaptable to genetic engineering. This principle has been demonstrated with retroviral and lentiviral vectors in CD34 + HSC (immature) [189, [191] [192] [193] [194] ], but not progenitor T cells. As progenitor T cells are cycling and renewed in the OP9-DL1 coculture system, it is likely they will prove equally amenable to genetic manipulation. Thus, together with the current assays presently used with mouse T cell development, there are many different approaches that can now be easily applied to the study of human T cell development.
In contrast to mouse ESCs, undifferentiated human ESCs
have not yet generated progenitor cells that can give rise to T cells following coculture with OP9-DL1 cells. Indeed, the differentiation of human ESCs in OP9-DL1 coculture has proven more challenging. Several groups have demonstrated efficient differentiation of human ESCs into CD34 + cells through embryonic body formation [195] [196] [197] [198] [199] or coculture on S17 [200] , MS5 or OP9 [201] stromal lines. These CD34 + cells when sorted and re-cultured onto bone marrow stroma give rise to B [201] and NK [201, 202] cells and dendritic cells [160] [203] , suggesting that human ESCs may be less sensitive in vitro to Delta-likeNotch induced differentiation signals than mouse ESCs to promote T cell differentiation. Alternatively, the OP9-DL1 cells may not completely substitute for all of the factors required for the induction and early differentiation of human ESCs. This issue has recently been circumvented in vivo through the direct injection of human ESC-derived GFPlabeled CD34 + cells into conjoint human thymic/liver (Thy/Liv) tissues implanted under the kidney capsule into sublethally irradiated immunodeficient SCID-mice [204, 205] .
The ability to derive T cells from human ESCs remains an attractive goal for the treatment of immune-related disorders. This is due to the general consensus that theoretically, unlimited numbers of human T cells may be generated from undifferentiated human ESC cell lines, whereas human HSCs may possess only limited differentiation and proliferation potential from exhaustible sources such as bone marrow and cord blood. Foresight not withstanding, only a small number of human HSCs can be isolated from limited tissue and therefore must be properly stored and expanded for future use. Efforts to expand human HSCs numbers while preventing their differentiation are under development and could be utilized in concert to generate even greater numbers of progenitor T cells. Taken into consideration that not all HSCs exhibit long-term reconstitution potential, and the thymus does not contain progenitor cells that self-renew, the utilization of HSCs and progenitor T cells may have limited niches for the treatment of T cell based immunodeficiency or autoimmunity. Human ESCs are not without their drawbacks and serious concerns remain about their safety given their genomic instability, epigenetic status, their propensity spontaneous differentiation and their potential to cause cancer [206] [207] [208] [209] .
In the OP9-DL1 coculture system, human HSCs derived from cord blood and bone marrow show robust expansion. Indeed, the OP9-DL1 system generates a population of T lineage cells that are highly homogenous and easily isolated based on human markers of T cell differentiation. This system generates T lineage cells efficiently (>90%) at the expense of other lymphocytes and myeloid cells; however, the upper-limit of this T cell expansion is unknown. The output of progenitor-T cells in this coculture system is at least 10 3 -10 5 times higher than other in vitro systems suggesting that further scaling-up of this system could yield clinically relevant numbers to achieve therapeutic benefits in patients with immune related disorders. Long term OP9-DL1 cocultures initiated with human CD34
+ CD38
-cells demonstrate sustained T cell development for at least 120 days and retain a population of cells, which are CD34 + CD7 + . Whether these cells are capable of self-renewal is unclear, although multiple waves of T cell development have been observed in longterm OP9-DL1 cocultures [La Motte-Mohs, unpublished observations]. These waves of T cell development could simply reflect apoptosis of CD4 + CD8 + DP T cell populations that did not receive positive and negative selection signals followed by the re-emergence of progenitor T cells derived from early progenitors maintained in OP9-DL1 cultures. Indeed, such a possibility is consistent with the dual role of Notch signaling in maintaining progenitor cell renewal and promoting T cell differentiation [108] . Further studies are required to determine whether the OP9-DL1 coculture system promotes both T cell differentiation and self-renewal at the same time. Immune-engraftment/reconstitution studies into immunodeficient mice are also required to determine whether cells derived from OP9-DL1 cocultures exhibit long-term or short-term repopulation potential.
Although the differentiation from stem cell to functional T cell can be obtained readily by coculture on OP9-DL1 cells [144, 145] , there are still some drawbacks to this system. For instance, OP9 cells express mouse MHC class I molecules and support the differentiation of mouse HSCs into CD8 + T cells, but do not express mouse MHC class II molecules and do not appear to express CD1d; thus, limiting their ability to support the differentiation of CD4 T cells and NKT cells, respectively [145, 171] . While there is evidence that mouse MHC molecules can support the differentiation of human HSCs [119, 210] , this could be especially problematic when developing cellular immune-therapies to treat immune-related disorders without invoking an autoimmune response or graft-verses host disease (GvHD). However, OP9-DL1 cells could be modified to ectopically express human MHC molecules, which would permit a re-examination of the contributions of these molecules to the development of specific subsets of T cells as well as generate MHC-matched T cells to an individual. Specifically, we have reported the robust and sustained generation of human T cells to the DP stage from cord blood-derived HSCs; however, the generation of CD4 + or CD8 + SP T cells has been limited [19] , which is likely due to the absence of human HLA molecules on mouse OP9-DL1 cells. Strikingly, under long-term densely packed coculture conditions we can detect CD4 + or CD8 + T cells that express TCR [unpublished observations, Ross La Motte-Mohs]. At first glance, the emergence of human single positive T cells seems difficult to reconcile given the published reports that isolation of human progenitor T cells require human thymic stromal elements to realize their full differentiation potential towards SP T cells. Nevertheless, a recent paper by Choi et al. demonstrated that thymocyte-thymocyte (T-T) interactions can mediate positive selection and promote the maturation of CD4 T cells in the absence of MHC-class II + thymic stroma [211] . Similarly, the emergence of human CD4 Interestingly, another drawback is the limited number of self-antigens that OP9-DL1 cells are likely to present to developing T cells. Initially, OP9 cells, in contrast to thymic medullary epithelial cells, were thought unlikely to express the AIRE gene [74] and mediate ectopic self-antigen presentation for peripheral tolerance. However the detection of low levels AIRE message in OP9-DL1 cells [personal communication, Lynn Rumfelt] suggests that OP9-DL1 cells may posses some capacity to present tissue-specific-antigens, such as insulin, which was also detected in OP9 cells. Whether the AIRE transcription factor is functional in OP9-DL1 cells remains to be confirmed experimentally. However, the recent demonstration that skin cells that express AIRE and Delta-like-1 can support thymic-independent T cell development and mediate negative selection [147] , suggests a similar possibility for the OP9-DL1 cells. Thus, questions dealing with the mechanisms responsible for positive and/or negative selection of the TCR repertoire can be investigated by appropriately manipulating the OP9-DL1 cells and are currently under investigation in our laboratory. Nonetheless, issues related to the ability or function of OP9-DL1 cells to properly select mature T cells can be avoided by simply transferring CD4 -CD8 -double negative progenitors or immature CD4 + CD8 + T cells, obtained from stem cells cultured on OP9-DL1 cells, into FTOC or intrathymically into host mice [144] . Such an approach not only provides a practical solution to the self-MHC restriction and tolerance issues, but also opens new avenues for future possibilities to test the immune function of the in vitro-derived T cells as well as their efficacy in adapting T cells to treat human immune-related disorders.
These studies underline valid concerns to determine the efficacy and therapeutic effectiveness for the utilization of in vitro-derived progenitor T cells for the treatment of immunerelated disorders. Progenitor T cells, whether autologous, or allogeneic, generated in the OP9-DL1 system are immature and still need to undergo positive and negative selection in the host thymus. This suggests that they are unlikely to evoke an autoimmune response or GvHD in vivo. Although GvHD remains a concern in stem cell transplantation, the reconstitution of a human immune system using CD34 + HSC, but not progenitor T cells, in both patients and immunodeficient mice have demonstrated the principle of this approach [189, 210, 212, 213] . Indeed, the utilization of human/mouse models of engraftment [16] may prove particularly useful in helping to evaluate the safety of in vitro derived human progenitor T cells for the treatment of immune-related disorders.
IMMUNE ENGRAFTMENT
The study of human hematopoiesis employing mouse models first arose in the late 1980's following the discovery of the scid (severe combined immune deficiency) mutation in the C.B-17 mouse strain [214] . Such mice harbor a mutation in the prkdc (protein kinase DNA catalytic protein) gene involved in non-homologous end joining during TCR and immunoglobulin rearrangement [214] , thus, lacking both mature T and B cells. Soon after, C.B-17 SCID mice were used by McCune et al. [215] as an experimental system for studying human T cell development in relation to HIV-1. Using this model, (SCID/hu (thy/liv) model) fragments of human fetal thymus and fetal liver are placed under the kidney capsule of the animal and the graft is allowed to vascularize. Fetal liver provides a rich source of human HSCs and the fetal thymus provides the environment where the HSCs can differentiate into T cells. Although it was a groundbreaking model for studying human lymphocyte development in vivo, most of the engrafted cells were restricted to the fetal explants without seeding the mouse bone marrow or other tissues.
Models were then employed to better reflect the ability of human hematopoietic cells to home and differentiate within the mouse environment without human fetal tissues. Many groups were able to demonstrate that sublethally irradiated C.B-17 SCID mice support the engraftment and differentiation of CD34 + progenitor cells from human bone marrow and human cord blood [216, 217] into multiple hemopoietic lineages. In light of this, CD34 + stem cells were coined 'SCID repopulating cells' (SRC) as they were capable of repopulating hematopoietic lineages in a SCID mouse. Unfortunately, the levels of engraftment were quite low and T cell development in particular was typically absent. A major barrier to this engraftment was innate immune function still present in the SCID mice. In particular, NK cell function was a critical factor determining host resistance to xeno-engraftment. Use of the non-obese diabetic mouse (NOD) aided tremendously in facilitating human cell engraftment. The inbred NOD mouse strain lacks many aspects of innate immune function due to: (1) complement deficiency due to a mutation in the C5 gene [218] (2), compromised NK function and (3) defects in macrophage function due to reduced IL-1 secretion. Indeed, introduction of the SCID mutation onto the NOD background (NOD/SCID) has allowed for successful human engraftment by many groups and is widely used for the study of human hematopoiesis and HSCs [219, 220] . Importantly, Kerre et al. demonstrated robust T cell development, albeit in a low percentage of mice, using NOD/SCID animals treated with an antibody blocking murine IL-2R , thus further lowering NK function [219] . -/-mouse strains as IL-15R c is critical for their development [221] , thus improving human immune engraftment [16, 219, 222] . Recently, Traggiai and colleagues [210] demonstrated that newborn RAG2 -/-c -/-transplanted with human CD34 + CB cells, developed all major immune cell subsets. Strikingly, T-lymphopoiesis was supported at high levels, in contrast to the inefficiency of earlier models. The study by Traggiai et al. also demonstrated that human T cells can populate the peripheral organs and elicit anti-viral immune responses indicating that engrafted human HSCs differentiate and undergo positive selection events [210] . Accordingly, it has been suggested that human T cells undergoing positive selection in the thymus of an immunodeficient mouse would therefore be biased towards mouse MHC molecules and may require transplantation of human thymic fragments to observe selection on human MHC class molecules [16] . Alternatively, the type of APC used to present viral antigens or the targeted tissue used by infections agents could determine whether human T cells are positively selected on mouse or human MHC molecules. The study by Traggiai et al. seems to support the former possibility given that Epstein-Barr Virus (EBV) infects human B cells which can present viral epitopes in the context of human MHC molecules [210] . Clearly, in vivo models with a superior capacity to accept human immune grafts are available, rendering them as powerful tools to gain insight into human hematolymphoid development and to test the safety of in vitro derived progenitor T cells in the treatment of immune disorders of the T cell lineage.
THERAPEUTIC POTENTIAL
The ability to generate in vitro-derived human progenitor T cells and to test their safety in human/mouse immune engraftment models, opens avenues for cellular based approaches for treating immune-related disorders of the T lineage [16, 223] . T cells are the major effector arm of the adaptive immune system in recognizing and eliminating viral and bacterial pathogens. In certain rare blood cancers such as T cell acute lymphoblastic leukemia (T-ALL), T cells proliferate crowding out healthy immune cells and perturbing normal immune function [113, 224] . Although chemotherapy can often impart therapeutic benefits in cancer patients, it often can lead to immunodeficiency and susceptibility to opportunistic infections. Opportunistic infections also pose a serious concern in AIDS patients whose CD4 + T cells have been depleted following infection with HIV. While immunodeficiency remains a serious concern in HIV/AIDS and cancer, immune-hypereactivity is equally problematic in autoimmune disease where T cells that lack proper regulatory control, make immune responses to self-tissue.
Given this spectrum, a system that could restore T cell numbers and normal immune function would be desirable for the treatment of immune-disorders of the T cell lineage. The OP9-DL1 coculture system is capable of generating large numbers of human progenitor T cells in vitro. However, their capacity to impart therapeutic effectiveness for the treatment of T cell disorders requires further investigation. The ability to move this system towards serum-free conditions [225] , as has been done with the development of human ESC lines [226] , and to test progenitor T cells in human/mouseimmune engraftment models [16] would facilitate into the clinic the emergence of novel cellular-based therapies utilizing in vitro derived progenitor T cells.
CANCER
In 2005, nearly 128,000 individuals were diagnosed with myeloma, lymphoma and leukemia in North America (US & Canada). Following aggressive myeloablative-chemo/radiotherapy of these blood cancers, these individuals may become immunodeficient and require stem cell transplantation to replace or restore their immune system. Indeed, every year in North America 9,000 individuals undergo stem cell transplantation. Although, HSCs may be obtained from bone marrow, GM-CSF-mobilized peripheral blood, or cord blood, several clinical challenges present themselves in most stem cell transplantations: from finding a suitably major-histocompatible matched donor, to preventing GvHD, to successful engraftment of a donor immune system onto the host [227] . Most immune cells recover quickly following transplantation, but T cells take the most time (~2 years) to recover in terms of cell numbers and function [228] . This is perhaps dictated by the broad repertoire of TCRs required to cover the range of environmental and pathogenic antigens that an individual will be exposed to. Until that broad repertoire is re-established, gaps may exist that permit the emergence of opportunistic infections.
The core value of the OP9-DL1 coculture system is the potential to re-establish quickly T cell reconstitution and function in orphan status cancers where immunodeficiency is a significant concern. This approach may be quite useful in cases where aggressive chemotherapy in T-ALL has failed [113, 224, 229] . Although more proof-of-principle research is required to support their therapeutic potential, the OP9-DL1 coculture system, which generates large numbers of progenitor T cells, offers several advantages. First and foremost, the use of a cellular therapy, for example progenitor T cells, would be given in a clinical setting where cell replacement, specifically CD34 + HSCs, is an established mode of treatment [223, 230] .
With regard to cancer treatments, the OP9-DL1 coculture system lends itself towards future genetic approaches to create designer T cells specifically tailored to target tumor cells and/or deliver chemotherapeutic agents. Such approaches are not so far-fetched. For example, progenitor T cells could be manufactured to recognize tumor-specific antigens found in certain breast cancers as well as Burkitt's lymphoma, neuroblastoma, malignant melanoma, osteosarcoma, and renal cell carcinoma [231] . One example of this genetic approach utilizing CD8 + Wilms' tumor (WT1) gene-specific cytotoxic Tlymphocyte clones for the treatment of Chronic Myeloid Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL). Thus, it is easy to envision a future in which progenitor T cell transplantation could be used as an adjuvant therapy with stem cell transplantation to quickly reconstitute the T cell compartment in patients with terminal illness or specifically target cancer cells for destruction [223] .
HIV/AIDS
Acquired Immunodeficiency Syndrome (AIDS), which follows the infection with the Human Immunodeficiency Virus (HIV), is characterized by a chronic decline in the number of CD4 helper T cells. The CD4 T cell is a critical immune or white-blood cell that helps to maintain the function of "killer" CD8 cytotoxic T cells, which lyse virusinfected cells [232] . AIDS has become a global pandemic with an estimated 38 million people living with the disease worldwide and 1.6 million cases in North America alone. Current treatment regimens including the highly active antiretroviral therapy (HAART), a combination of several anti-HIV drugs [i.e. Viramune (nevirapine), Rescriptor (delavirdine), Invirase (saquinavir), and Norvir (ritonavir)], have been effective in reducing viral load and extending the life-span of HIV-infected individuals but have proven difficult to implement/achieve/maintain over long-periods of times for a variety or reasons (i.e. toxicity, financial burden, government apathy, and evolving resistance of HIV to these drugs). Indeed, HAART is often given in cycles with 'vacations'/break periods to allow the patient to recover from antiviral drug induced toxicity. As a result there is continued interest to find more efficacious drugs and/or cellular based therapies (i.e. vaccines or stem cell approaches) that keep pace with the evolving resistance of HIV and would augment or replace current treatment regimens to restore or maintain T cell numbers.
In the case of HIV/AIDS, the core value of the OP9-DL1 coculture system may be the ability to create large numbers of in vitro-generated progenitor T cells that would offer therapeutic benefits to individuals that HAART has failed or that have gone off HAART due to drug toxicity. One competitive advantage of a progenitor T cell based therapy would be minimal toxicity and side-effects of these cells compared to anti-retrovirals. Given, that few treatment options are available to this subpopulation of individuals that have failed HAART, the use of progenitor T cells could be a viable option. Although these progenitor T cells and their CD4 + progeny would again be subject to HIV infection in vivo and require multiple treatments, the capacity to expand noninfected cells in vitro and restore T cell numbers in vivo may help to restore immune function and limit the emergence of opportunistic infections for some time during periods of planned HAART 'vacation' or failure. This presents two future extensions of this technology for therapeutic potential. First, the OP9-DL1 coculture system may have therapeutic potential as an adjuvant therapy in combination with HAART, or as a stand-alone therapy when HAART is periodically discontinued. As with the case of cancer, the OP9-DL1 coculture system lends itself towards emerging genetic approaches to create designer T cells resistant to HIV infection. One example of such an innovative approach would be the expression of the mutant form of the chemokine coreceptor CCR5 that blocks viral infection [233, 234] in progenitor T cells. Such an approach would offer a novel means to treat HIV/AIDS by preventing HIV infection and thus maintaining T cell numbers and T cell function and is no longer far-fetched as several clinical trials have been approved for the treatment of HIV/AIDS using genetically modified mature-CD4 + T cells and CD34 + HSCs, but not progenitor T cells.
AUTOIMMUNITY
Traditionally, tolerance was thought to be established centrally in the thymus to self-antigen presented by thymic cells and blood-borne self-antigens, while T cells with specificity towards tissue-specific antigens underwent tolerance induction in the periphery [235] . The recent observation that thymic epithelial cells that express the AIRE gene can promote the promiscuous expression of tissue-restricted antigens has yielded new insights for how self-tolerance is maintained and broken [235] . Autoimmune diseases result from the dysregulation or breakdown of the processes that maintain self-tolerance in the periphery. Many investigators have demonstrated that a population of T cells with regulatory activity (T Reg ) can suppress pathological immune responses in murine models of autoimmune disease, transplantation and GvHD [236] suggesting that these cells could be utilized therapeutically to treat human autoimmune disease [59, 237] . T Reg cells express CD4 and CD25 as wells as the forkhead transcription factor boxP3 (Foxp3) [238] , which serves as a master regulator for T Reg development and function [239, 240] . Indeed, Foxp3-mutant mice have a deficiency in T Reg cells and develop severe lymphoproliferative autoimmune syndrome. Similarly, humans with the rare recessive disorder: Immunodysregulation, Polyendocrinopathy and Enteropathy X-linked (IPEX) syndrome exhibit aggressive autoimmunity and early death [241] .
T Reg cells can be generated both in the thymus and in the periphery and appear phenotypically and functionally similar. Studies with TCR-transgenic systems indicate that relatively high-affinity interactions of TCR with self-peptide agonists presented on thymic epithelial cells are required to efficiently generate T Reg cells in a CD28-dependent manner [242] [243] [244] [245] . As a result, intrathymic T Reg cells utilize a diverse TCR repertoire [246] skewed toward autoantigen recognition. Recently, it was demonstrated Hassall's corpuscles express thymic stromal lymphopoietin (TSLP), which activates thymic dendritic cells to induce the proliferation of T Reg cells [247] . Alternatively, T Reg cells can be expanded extrathymically through differences in self-peptide exposure and cytokine milieu (i.e. transforming growth factor-(TGF-) and IL-10) [248] [249] [250] [251] .
The observation that T Reg cells are deficient in patients with multiple sclerosis, type 1 diabetes, rheumatoid arthritis [252] [253] [254] has raised hope that treatment of these and other autoimmune diseases may rest with the restoration of T Reg cells [59, 237] . In contrast, the elimination of T Reg cells may play a significant role in enhancing cancer immunotherapeutic approaches by releasing the breaks on antitumor T cell responses and inducing limited local autoimmunity [255] . Finally, T Reg cells may play a critical role in the establishment of tolerance following allogenic organ transplant thereby minimizing rejection mediated by GvHD [256] [257] [258] .
As with most cellular based therapies, the major obstacle for the utilization of T Reg cells in the treatment of autoimmunity is the ability to generate them in large numbers to realize therapeutic effectiveness. Currently, the OP9-DL1 coculture system does not support the generation of large numbers of T Reg cells from progenitor T cells. Given the role of TSLP in the generation of T Reg cells [247] , it is unclear whether the absence of T Reg cells in the OP9-DL1 coculture system is due to a deficiency of OP9 cells to produce TSLP. Should this be the case, retroviral transduction of OP9-DL1 cells to produce TSLP may promote their emergence. Alternatively, it may be possible to generate T Reg cells from CD4 + CD25 -cells following OP9-DL1 coculture with cytokines, such as TGF or IL-10, known to enhance their proliferation and differentiation [249] [250] [251] .
Regardless, stem cell transplantation for the treatment of severe autoimmunity is gaining momentum [59, 237, 257, 259] with the development of human/immunodeficient mouse models of alloreaction [260] , methods to expand regulatory T cell populations [261] and to engineer stem cells and progenitor T cells to express self-antigen [262] .
CONCLUSIONS
The ability to generate large numbers of progenitor T cells in vitro opens novel therapeutic avenues for the treatment of immune-related disorders of the T cell lineage. To date, the only in vitro system capable of generating human T cells in large numbers is the OP9-DL1 coculture system. The upper limits of progenitor T cells expansion from rare cord blood derived HSCs remain undefined. However, the OP9-DL1 seems amenable to upscale coculture to yield therapeutically relevant numbers. Further development of this coculture system is required before in vitro derived progenitor T cells can reach the clinic and offer therapeutic effectiveness for the treatment of a broad range of T cell related disorders, such as cancer, HIV/AIDS and autoimmunity. The precedence for the utilization of progenitor T cells as a cellular replacement therapy in T cell immunodeficiencies has been established through the allogeneic bone marrow transplantation [223] . Although, further investigation is needed to determine safety and efficacy of progenitor T cells, the reconstitution of human T cells into immunodeficient mouse models may help to address some of these concerns by establishing mouse models of human disease. The OP9-DL1 system may prove amenable to several emerging technologies that permit the genetic modification of stem cells, progenitor T cells and their specific T cell progeny such as anti-tumor specific cytotoxic CD8 + T cells, HIV-resistant CD4 + T cells, as T Reg cells. Finally, the OP9-DL1 coculture system may interface with alternative differentiation strategies for human embryonic stem cells offering an inexhaustible source of HSCs and progenitor T cells for the treatment of immune related disorders such as cancer, HIV/AIDS, and autoimmunity. 
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